<DOC>
	<DOCNO>NCT00394433</DOCNO>
	<brief_summary>The purpose research study determine combination docetaxel , cisplatin , irinotecan bevacizumab help shrink metastatic esophageal gastric cancer cancer respond combination . Bevacizumab new drug believe stop formation new blood vessel carry nutrient tumor . Bevacizumab approve use metastatic colon rectal cancer . Docetaxel , cisplatin irinotecan traditional chemotherapy agent test together another clinical trial esophageal gastric cancer . It hop add bevacizumab regimen make treatment effective .</brief_summary>
	<brief_title>Docetaxel , Cisplatin , Irinotecan Bevacizumab ( TPCA ) Metastatic Esophageal Gastric Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary To determine 10-month progression-free survival rate combination TPC Bevacizumab patient metastatic esophageal gastric cancer Secondary - To determine response rate ( RECIST ) median duration response - To determine overall survival - To determine toxicity Exploratory - To explore 7/7 7/6 UGT1A1 polymorphism correlate grade III/IV irinotecan-related diarrhea neutropenia irinotecan give relatively low dose patient esophageal gastric cancer - To correlate expression tumoral serum VEGF response survival - To correlate TGF alpha level tumor microvessel density clinical activity - To examine circulate endothelial cell ( CECs ) surrogate marker antitumor activity bevacizumab DESIGN This trial use single stage design differentiate &gt; /= 50 % rate 10-month progression-free survival &lt; /= 30 % rate . The propose regimen would promise least 15 35 patient alive progression-free 10 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm , unresectable esophageal gastric carcinoma ( carcinoma=adenocarcinoma squamous cell carcinoma ) Measurable disease great equal 1 cm ( long diameter ) spiral compute tomography ( CT ) scan 2 cm great radiographic technique Lesions must measurable least one dimension Bone lesion , ascites , effusion measurable 18 year age old ECOG performance status 0 1 Life expectancy least 12 week Adequate bone marrow function Adequate renal function Adequate liver function Prior chemotherapy ( except part pre postoperative therapy , complete 1 year prior start day protocol ) History severe hypersensitivity bevacizumab , docetaxel , cisplatin , irinotecan , drug formulate polysorbate 80 Current , recent ( within 4 week ) plan participation experimental drug study Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure , fine needle aspiration , portacath placement , core biopsy within 7 day prior Day 0 study Myocardial infarction stroke past 6 month Blood pressure &gt; 150/100 mmHg Unstable angina New York Heart Association ( NYHA ) grade II great congestive heart failure Clinically significant peripheral vascular disease Persistent bleed primary tumor , anticoagulant , require repeat transfusion Evidence bleed diathesis coagulopathy Uncontrolled serious medical psychiatric illness Uncontrolled diarrhea Peripheral neuropathy &gt; grade 1 Clinically apparent central nervous system metastases carcinomatous meningitis Other active malignancy nonmelanoma skin cancer situ cervical carcinoma . Urine protein : creatinine ratio 1.0 great screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 1 Serious nonhealing wound , ulcer , bone fracture Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>TPCA</keyword>
	<keyword>Taxotere</keyword>
	<keyword>Platinum</keyword>
	<keyword>Avastin</keyword>
	<keyword>Camptosar</keyword>
	<keyword>gastric cancer</keyword>
</DOC>